Erythromycinum

Erythromycin (base); IUPAC: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione · Erythromycin, Ilosone, Ilotycin, E-Mycin, Erythrocin; source organism Saccharopolyspora erythraea (formerly Streptomyces erythraeus)

Modern MM

A modern drug remedy with NO published formal proving. Any sphere of action is inferred from erythromycin's documented pharmacology and toxicology under the Law of Similars: chiefly the gastrointestinal tract (motilin-driven hypermotility, nausea, cramping, diarrhea), the liver (cholestatic jaundice), the ear (tinnitus/transient deafness), and cardiac rhythm (QT prolongation). Used in practice mainly as a tautopathic/isopathic remedy for after-effects of erythromycin therapy. No mind or constitutional picture is established.

Key symptoms

No keynotes exist from a proving. Toxicologically-derived indications (Law of Similars / tautopathy) center on: gastrointestinal hypermotility — nausea, vomiting, epigastric and abdominal cramping, diarrhea; cholestatic jaundice with right-hypochondrial discomfort; tinnitus and transient hearing loss; palpitations from QT prolongation. Principal practical use is tautopathic — to address lingering ill-effects following erythromycin/macrolide antibiotic courses.

Worse (aggravation)

Not established — no proving data. Modalities cannot be stated from verified sources.

Better (amelioration)

Not established — no proving data. Modalities cannot be stated from verified sources.

Manohar V Nagaiah

Materia Medica of Modern Homeopathic Medicine · 2026

Erythromycin, Ilosone, Ilotycin, E-Mycin, Erythrocin; source organism Saccharopolyspora erythraea (formerly Streptomyces erythraeus)

Source & Nature

ERYTHROMYCINUM is prepared from erythromycin, a 14-membered macrolide antibiotic (C37H67NO13, MW 733.9, CAS 114-07-8, PubChem CID 12560) produced as a fermentation metabolite of the soil actinomycete Saccharopolyspora erythraea (formerly Streptomyces erythraeus). The producing organism was isolated from a 1949 Philippine (Iloilo) soil sample submitted by Abelardo Aguilar and developed by Eli Lilly (marketed from c.1952 as Ilosone/Ilotycin). It acts therapeutically by inhibiting bacterial 50S ribosomal protein synthesis and, independently, as a potent motilin-receptor agonist driving gastrointestinal motility.

Continue Modern MM in the app

Classical texts are in the public domain. Educational reference only — not medical advice.